Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease.

International journal of molecular sciences - 6 Jan 2023

Monticelli Maria, Hay Mele Bruno, Allocca Mariateresa, Liguori Ludovica, Lukas Jan, Monti Maria Chiara, Morretta Elva, Cubellis Maria Vittoria, Andreotti Giuseppina

Abstract excerpt

Fabry disease is a lysosomal storage disease caused by mutations in the GLA gene that encodes alpha-galactosidase (AGAL). The disease causes abnormal globotriaosylceramide (Gb3) storage in the lysosomes. Variants responsible for the genotypic spectrum of Fabry disease include mutations that abolish enzymatic activity and those that cause protein instability. The latter can be successfully treated with small...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 1-Deoxynojirimycin
Share to alpha-Galactosidase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Curcumin

Share to Fabry Disease

Share to Galactose

Share to Lysosomes

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 36674610
DOI: 10.3390/ijms24021095
PMCID: PMC9863837

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease.PMID 36674610Read ↗

Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.Semantic proximity Read ↗

Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones.Semantic proximity Read ↗

Pharmacological chaperone therapy for Fabry disease.Semantic proximity Read ↗

A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.Semantic proximity Read ↗

Maturation of Lysosomal α-Galactosidase A and Implications for Fabry Disease.Semantic proximity Read ↗

Fabry Disease Therapy: State-of-the-Art and Current ChallengesSemantic proximity Read ↗

Fabry disease: Mechanism and therapeutics strategiesSemantic proximity Read ↗

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models.Semantic proximity Read ↗

Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice.Semantic proximity Read ↗

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studiesSemantic proximity Read ↗

GLA Mutations Suppress Autophagy and Stimulate Lysosome Generation in Fabry Disease.Semantic proximity Read ↗

Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.